Senior peer exchange across the full continuum — from target identification to supply chain. Curated rooms. Real challenges. Conversations that accelerate the science.
Drug discovery is one of the hardest endeavours in science. The challenges at every stage don't get solved in isolation.
They get solved when the right people are in the right room.
Cascade creates the conditions for those conversations. Small rooms, curated attendees, candid exchange between people who understand the weight of the problems on the table.
Read Our StoryDisease biology, target validation, the foundation of every pipeline.
In vitro, in vivo, biomarker strategy. Where hypotheses meet biological reality.
Trial design, patient stratification, endpoint selection, data readouts.
Navigating the approval landscape. Translating evidence into access.
CMC strategy, process development, supply resilience.
10 senior decision makers. A single challenging topic. An environment built for candour.
Flagship50–100 delegates. Focused agenda. Structured debate and peer-to-peer working groups.
GrowingA standing community for the most senior voices across the full continuum.
Coming SoonDelegates, sponsors, and community members — we'd like to hear from you.
Every Cascade Exchange event is built around a specific challenge. Curated delegates. Focused agenda. Candid exchange.
Our partners are not sponsors — they are part of the drug development ecosystem. Each brings tools, technology or expertise that moves the needle for the senior leaders in our community.
The Cascade Exchange is built on the principle that sponsors are part of the ecosystem — not outside it.
You're in the room with 15 heads of R&D who have budget, mandate and a genuine problem to solve. The conversation is the product.
Every delegate is verified. Seniority is a hard requirement. No procurement managers, no junior scientists attending on someone else's behalf.
One sponsor per category per event. No direct competitor in the room.
The Cascade Exchange is the entry point to a sustained community. Build lasting relationships, not one-night contacts.
In biology, a cascade is a sequence of reactions where each step amplifies the next. One signal triggers another until something meaningful happens at scale.
Drug discovery is one of the hardest endeavours in science. The journey from target identification to patient — through pre-clinical development, clinical trials, regulatory navigation, manufacturing and supply — is long, complex and brutally unforgiving.
Attrition is high. Timelines are punishing. And the challenges at every stage are shared challenges.
They get solved when the right people are in the right room.
The Cascade Exchange was built to create those rooms. Not conferences. Not panel discussions. Genuine peer exchange between the most senior minds across the drug development continuum.
One conversation starts a cascade. That is the idea.
Every delegate is vetted. Seniority is non-negotiable.
Chatham House rules as standard. No selling from the floor.
A single dinner is the start of a relationship, not the end of one.
Every event is designed around a challenge that matters.
The events are the start. The community is the asset. A standing peer network for the most senior minds — launching 2025.
The most valuable thing that happens at a Cascade Exchange event isn't on the agenda. It's the conversation that continues over dessert. The follow-up call two weeks later.
The Pharma Leaders Club is the infrastructure for those relationships to persist. Not a LinkedIn group. A genuine professional community with standards, structure, and consequence.
Members are invited to all events before public release.
Annual aggregate intelligence on key challenges across the community.
Specific, relevant introductions to peers facing the same challenges.
Closed-door sessions on emerging issues. Smaller, faster, more focused.
Shared thinking, sustained peer connection across the calendar year.
Members shape the topics The Cascade Exchange puts on the table.
Whether you're interested in attending an event, exploring sponsorship, or joining the Pharma Leaders Club — we'd like to hear from you. Every enquiry is handled personally.
The foundation of every pipeline — and the stage where the majority of attrition begins. Target identification, hit-to-lead, lead optimisation, and the brutal reality of translational failure.
Drug discovery has been transformed by AI-driven target identification, cryo-EM structural biology, and the explosion of multi-omics data. Yet despite these tools, attrition remains stubbornly high. The bottleneck is no longer data — it's interpretation, prioritisation, and the quality of decisions made under uncertainty.
Target validation remains the critical failure point. Genomics-derived targets often lack the translational evidence needed to justify investment. The pressure to progress candidates prematurely — driven by portfolio timelines and investor expectations — is a systemic challenge that no single organisation has solved in isolation.
Fragment-based drug design, covalent approaches, and targeted protein degradation (PROTACs, molecular glues) are expanding the druggable proteome — but also introducing new complexity in ADMET profiling and intellectual property strategy.
Where is machine learning genuinely accelerating target identification and lead optimisation? Where is it failing to deliver on the promise? A candid assessment from practitioners.
How do organisations distinguish between biologically interesting targets and clinically actionable ones? What evidence thresholds justify progression — and who decides?
PROTACs, molecular glues, covalent inhibitors, RNA-targeting small molecules. What is the current state of play and what are the practical barriers to development?
As platform technologies proliferate, how are discovery organisations deciding what to build internally versus access through CROs, biotechs, or academic partnerships?
Multi-omics, structural biology, phenotypic screening — how are organisations creating coherent signal from vast and heterogeneous datasets without losing speed?
Can better predictive models, biomarker strategies, and go/no-go criteria reduce late-stage attrition? What does a genuinely rigorous kill decision look like?
Drug Discovery dinners run quarterly across the UK.
The bridge between discovery and the clinic — and the stage where translational assumptions are most frequently exposed. In vivo pharmacology, toxicology, biomarker strategy, and the relentless pressure to predict human response from non-human systems.
Pre-clinical development sits at the sharpest edge of translational science. The question is never just "does it work in the model?" — it's "does the model tell us anything meaningful about what will happen in a human?"
The 3Rs framework continues to reshape in vivo study design, with organoids, microphysiological systems, and advanced ex vivo models increasingly integrated into pre-clinical packages. But regulatory acceptance of these alternatives remains inconsistent, creating a two-track development reality for many programmes.
Biomarker strategy at the pre-clinical stage has become a determinant of clinical programme quality. Translational biomarkers — particularly pharmacodynamic markers and early efficacy signals — are now expected by regulators and investors alike, placing new demands on pre-clinical teams that historically focused on safety and tolerability.
When a drug fails in Phase II for lack of efficacy, how much of the root cause sits in pre-clinical model selection? A frank conversation about accountability, model limitations, and what better looks like.
Organ-on-a-chip, 3D organoids, patient-derived models — where are these genuinely displacing animal studies, and where are they still supplemental? What does regulatory acceptance actually look like in practice?
How are leading organisations embedding translational biomarker strategy into pre-clinical design rather than retrofitting it? What makes a biomarker truly translatable?
ADCs, bispecifics, RNA therapies, cell and gene — each brings distinct pre-clinical challenges. How are organisations building expertise and regulatory strategy for modalities where the playbook is still being written?
As pre-clinical outsourcing deepens, how do sponsors maintain scientific oversight, data quality, and strategic control? What does a genuinely high-functioning CRO relationship look like?
Timeline pressure on IND-enabling studies is intensifying. How are pre-clinical leaders managing scope, quality, and risk as organisations push for faster INDs without compromising the data package?
Pre-Clinical dinners run quarterly across the UK.
The most capital-intensive phase of drug development — and the one where strategic decisions made years earlier either pay off or unravel. Trial design, patient stratification, endpoint selection, and the increasingly complex regulatory landscape that governs all of it.
Clinical development has never been more complex. Precision medicine and biomarker-driven stratification have transformed trial design — enabling smaller, faster, more targeted studies but also creating new challenges in patient recruitment, site selection, and regulatory negotiation.
Decentralised clinical trials (DCTs) accelerated dramatically during COVID-19 and are now a permanent feature of the landscape. The operational and regulatory implications — remote monitoring, electronic patient-reported outcomes, direct-to-patient logistics — are still being worked through by most organisations.
Regulatory pathways have become simultaneously more flexible and more demanding. Breakthrough Therapy Designation, PRIME, and Accelerated Approval offer real opportunity — but come with post-marketing commitments and confirmatory trial obligations that reshape commercial and development strategy for years after approval.
Recruitment remains the primary cause of trial delay. How are organisations rethinking site selection, patient identification, and protocol design to build trials that patients can actually participate in?
Platform trials, basket studies, umbrella trials — where are adaptive designs genuinely delivering and where are they adding complexity without commensurate benefit? A practitioner view.
The post-COVID reality. What has actually been adopted, what has been quietly abandoned, and what does a genuinely hybrid trial look like operationally in 2025?
Accelerated approvals based on surrogate endpoints have come under intense regulatory scrutiny. How do development teams make the case for novel endpoints — and manage the confirmatory trial commitment?
Biomarker stratification improves signal — but shrinks populations, increases companion diagnostic complexity, and raises recruitment costs. How are organisations optimising this trade-off?
RWE is increasingly expected by regulators as context for trial data. How are clinical development teams building RWE strategies from the start of programme design rather than as an afterthought?
Clinical Development dinners run quarterly across the UK.
The discipline that determines whether scientific and clinical success translates into patient access — and commercial return. Regulatory strategy, submission excellence, HTA navigation, pricing, and the increasingly complex interaction between regulators, payers, and the public health systems they serve.
Regulatory and market access has evolved from sequential gatekeeper functions into a single integrated strategic discipline. The organisations that treat regulatory strategy and HTA planning as separate workstreams consistently find themselves renegotiating trial design and evidence packages late in development when the cost of change is highest.
The EU Joint Clinical Assessment (JCA), mandatory from January 2025 for oncology and ATMPs, represents the most significant structural change to European market access in decades. Joint scientific consultation, harmonised dossier requirements, and a single clinical assessment feeding into member state pricing and reimbursement decisions are already forcing a fundamental rethink of European development strategy.
Accelerated pathways — Breakthrough Therapy, PRIME, Conditional Marketing Authorisation — have expanded access to regulatory flexibility but created new obligations. Post-marketing confirmatory trial requirements and the evolving landscape around Accelerated Approval reform in the US are reshaping the risk calculus for early approval strategies.
The Joint Clinical Assessment is now a reality for oncology and ATMP programmes. How are regulatory and market access leaders adapting development plans, dossier strategy, and internal processes to a fundamentally changed European landscape?
When should market access considerations first appear in development strategy? How are leading organisations embedding HTA requirements into protocol design, comparator selection, and endpoint choice from Phase II onwards?
Breakthrough Therapy, PRIME, Conditional Approval — the regulatory flexibility is real, but so are the post-marketing obligations. How do regulatory teams assess whether an accelerated strategy is genuinely advantageous?
Regulators and HTA bodies are increasingly requesting RWE to contextualise trial data. How are organisations building RWE strategies that satisfy regulatory requirements and genuinely strengthen the access case?
Patient-reported outcomes, preference studies, and patient engagement in trial design are moving from nice-to-have to expected. How are regulatory and clinical teams operationalising genuine patient centricity?
The Inflation Reduction Act has fundamentally altered US pricing dynamics. How are global pricing and market access strategies being restructured in response — and what does this mean for European reference pricing?
Regulatory & Market Access dinners run quarterly across the UK.
The discipline that turns scientific success into patient access — and where commercial ambition most frequently collides with operational reality. CMC strategy, process development, tech transfer, and the supply chain complexity of a globalised industry under increasing geopolitical pressure.
Manufacturing and supply chain has moved from operational function to strategic differentiator. The rise of biologics, ATMPs, and personalised medicines has introduced complexity that small-molecule era infrastructure was never designed to handle — and the regulatory expectations for CMC packages have intensified in parallel.
Tech transfer remains one of the highest-risk activities in drug development. The transition from clinical to commercial manufacturing — whether internal or via CDMO — is where programmes that survived clinical development can still fail. Process robustness, analytical method transfer, and scale-up characterisation are perennial vulnerabilities.
Supply chain resilience has become a strategic imperative following COVID-19. Geopolitical pressures on API sourcing from China and India have forced organisations to map and diversify supply chains that were previously treated as procurement functions. The BIOSECURE Act and its equivalents are reshaping long-term CDMO strategy.
The clinical-to-commercial transition remains one of the highest-risk moments in drug development. How are heads of CMC and manufacturing managing process characterisation, analytical transfer, and scale-up risk in practice?
The BIOSECURE Act and equivalent legislation in Europe are forcing a rethink of long-term CDMO partnerships. How are organisations assessing geopolitical risk and restructuring manufacturing footprints?
Cell and gene therapies, mRNA, ADCs, bispecifics — each demands fundamentally different manufacturing approaches. How are organisations building the capability and infrastructure, and where does outsourcing make strategic sense?
The regulatory case for continuous manufacturing is strong. The operational transition is harder. What does genuine adoption look like, and what are the barriers for organisations that want to move beyond batch?
Post-COVID supply chain mapping exercises revealed vulnerabilities most organisations had tolerated for decades. What does a genuinely resilient pharmaceutical supply chain look like — and what is it worth paying for?
Net zero commitments, solvent reduction, green chemistry, and water use targets are moving from corporate responsibility to operational priority. How are manufacturing leaders translating sustainability targets into process development decisions?
Manufacturing & Supply dinners run quarterly across the UK.